Literature DB >> 17926281

Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes.

Benjamin A Lipsky1, John A Weigelt, Vikas Gupta, Aaron Killian, Michael M Peng.   

Abstract

BACKGROUND: Infections involving skin, soft tissue, bone, or joint (SSTBJ) are common and often require hospitalization. There are currently few published studies on the epidemiology and clinical and economic outcomes of these infections, whether acquired in the community or healthcare setting, in a large population.
OBJECTIVE: To characterize outcomes of culture-proven SSTBJ infection in hospitalized patients, using information from a large database.
DESIGN: We identified patients hospitalized in 134 institutions during 2002-2003 for whom specific International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes and a culture-positive SSTBJ specimen were recorded. Patients were classified into 4 clinical groups based on the type and clinical severity of infection. Patients in each group were further classified on the basis of whether their infection was community acquired or healthcare associated and whether it was complicated or uncomplicated.
RESULTS: We identified 12,506 patients with culture-positive infections and categorized them as having cellulitis (37.3%), osteomyelitis or septic arthritis (22.4%), surgical wound infection (26.1%), device-associated or prosthesis infection (7.2%), or other SSTBJ infection (6.9%). Monomicrobial infection was reported for 59% of patients, 54.6% of whom had Staphylococcus aureus as the etiologic agent. Of all S. aureus isolates recovered, 1,121 (28.0%) of 4,007 were resistant to methicillin. Healthcare-associated infections accounted for 27.2% of cases and were associated with a significantly greater mortality rate, a longer length of stay, and greater hospital charges, compared with community-acquired infections. Patients with a complicated infection (78.4%) had a significantly greater mortality rate, a longer length of stay, and greater hospital charges, compared with patients with an uncomplicated infection.
CONCLUSIONS: SSTBJ infections are frequent among hospitalized patients. S. aureus caused infection in more than 50% of the patients studied, and 28.0% of the S. aureus isolates recovered were resistant to methicillin. Healthcare-associated and complicated infections are associated with a significantly higher mortality rate and more prolonged and expensive hospitalizations. These findings could assist in projects to revise current management strategies in order to optimize outcomes while restraining costs.

Entities:  

Mesh:

Year:  2007        PMID: 17926281     DOI: 10.1086/520743

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  38 in total

1.  Polymorphisms in cytokine genes IL6, TNF, IL10, IL17A and IFNG influence susceptibility to complicated skin and skin structure infections.

Authors:  M H T Stappers; Y Thys; M Oosting; T S Plantinga; M Ioana; P Reimnitz; J W Mouton; M G Netea; L A B Joosten; I C Gyssens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-07-15       Impact factor: 3.267

2.  Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients.

Authors:  Marcus J Zervos; Katherine Freeman; Lien Vo; Nadia Haque; Hiren Pokharna; Monika Raut; Myoung Kim
Journal:  J Clin Microbiol       Date:  2011-11-23       Impact factor: 5.948

3.  Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost.

Authors:  B A Lipsky; Y P Tabak; R S Johannes; L Vo; L Hyde; J A Weigelt
Journal:  Diabetologia       Date:  2010-02-10       Impact factor: 10.122

Review 4.  Factors associated with variation in estimates of the cost of resistant infections.

Authors:  Bevin Cohen; Elaine L Larson; Patricia W Stone; Matthew Neidell; Sherry A Glied
Journal:  Med Care       Date:  2010-09       Impact factor: 2.983

5.  Skin and soft tissue infections in hospitalized and critically ill patients: a nationwide population-based study.

Authors:  Hsiu-Nien Shen; Chin-Li Lu
Journal:  BMC Infect Dis       Date:  2010-06-04       Impact factor: 3.090

6.  Cost comparison of linezolid versus vancomycin for treatment of complicated skin and skin-structure infection caused by methicillin-resistant Staphylococcus aureus in Quebec.

Authors:  Martine Pettigrew; Daniel Jg Thirion; Michael Libman; Giovanni Zanotti
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

Review 7.  Bone and joint infections due to anaerobic bacteria: an analysis of 61 cases and review of the literature.

Authors:  G Walter; M Vernier; P O Pinelli; M Million; M Coulange; P Seng; A Stein
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-28       Impact factor: 3.267

8.  Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections.

Authors:  R Vick-Fragoso; G Hernández-Oliva; J Cruz-Alcázar; C F Amábile-Cuevas; P Arvis; P Reimnitz; J R Bogner
Journal:  Infection       Date:  2009-09-18       Impact factor: 3.553

9.  Antibiotic prescribing practices in a multicenter cohort of patients hospitalized for acute bacterial skin and skin structure infection.

Authors:  Timothy C Jenkins; Bryan C Knepper; S Jason Moore; Sean T O'Leary; Carla C Saveli; Sean W Pawlowski; Daniel M Perlman; Bruce D McCollister; William J Burman
Journal:  Infect Control Hosp Epidemiol       Date:  2014-08-20       Impact factor: 3.254

Review 10.  Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials.

Authors:  Brad Spellberg; George H Talbot; Helen W Boucher; John S Bradley; David Gilbert; W Michael Scheld; John Edwards; John G Bartlett
Journal:  Clin Infect Dis       Date:  2009-08-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.